Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.83 |
| ▸ | KDR | P35968 | 12/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29317847 | 0.91 | DDR2 (1.00) | DDR2KDRPDGFRAMETFGFR2 | |
| SCHEMBL30050488 | 0.91 | DDR2 (1.00) | DDR2KDRPDGFRAMETFGFR2 | |
| SCHEMBL29317854 | 0.89 | DDR2 (0.83) | DDR2KDRPDGFRAMETSRC | |
| SCHEMBL30050292 | 0.89 | DDR2 (0.83) | DDR2KDRPDGFRAMETSRC | |
| SCHEMBL30051291 | 0.88 | DDR2 (0.82) | DDR2KDRPDGFRAMETFGFR2 | |
| SCHEMBL29186589 | 0.88 | DDR2 (0.82) | DDR2KDRPDGFRAMETSRC | |
| SCHEMBL29317860 | 0.88 | DDR2 (0.82) | DDR2KDRPDGFRAMETFGFR2 | |
| SCHEMBL29186568 | 0.88 | DDR2 (0.82) | DDR2KDRPDGFRAMETFGFR2 | |
| SCHEMBL30049816 | 0.88 | DDR2 (0.82) | DDR2KDRPDGFRAMETSRC | |
| SCHEMBL30050295 | 0.88 | DDR2 (0.82) | DDR2KDRPDGFRAMETFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | DDR2 4341/4885KDR 4885/4885PDGFRA 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.